{"id":"baffr-car-t","safety":{"commonSideEffects":[{"rate":"null","effect":"Cytokine release syndrome"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BAFFR CAR-T is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells expressing BAFFR.","oneSentence":"CAR-T cell therapy targeting BAFFR","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T05:39:30.093Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT07369492","phase":"PHASE1","title":"Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma","status":"RECRUITING","sponsor":"Jiangsu Topcel-KH Pharmaceutical Co., Ltd.","startDate":"2026-01-01","conditions":"B-cell Lymphoma","enrollment":30},{"nctId":"NCT06191887","phase":"PHASE1","title":"B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-18","conditions":"B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":27},{"nctId":"NCT04690595","phase":"PHASE1","title":"BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL","status":"ACTIVE_NOT_RECRUITING","sponsor":"PeproMene Bio, Inc.","startDate":"2021-05-18","conditions":"Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia","enrollment":24},{"nctId":"NCT07383233","phase":"PHASE1","title":"CD19/BAFF-R in Vivo CAR-T Cell Therapy Targeting Relapsed/Refractory B Cell Acute Leukemia/Malignant Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Qi deng","startDate":"2026-06-01","conditions":"Lymphoma, CAR T Cell Therapy, Acute Leukemia","enrollment":18},{"nctId":"NCT07345728","phase":"NA","title":"Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies","status":"RECRUITING","sponsor":"Donghua Zhang","startDate":"2026-01-01","conditions":"Relapsed/Refractory B-cell Malignancies","enrollment":28},{"nctId":"NCT07259070","phase":"PHASE1, PHASE2","title":"Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-11-29","conditions":"DLBCL, CLL, FL","enrollment":20},{"nctId":"NCT05370430","phase":"PHASE1","title":"BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL","status":"RECRUITING","sponsor":"PeproMene Bio, Inc.","startDate":"2022-06-13","conditions":"Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","enrollment":36},{"nctId":"NCT07196111","phase":"EARLY_PHASE1","title":"BAFFR CAR-T Treatment for Relapsed/Refractory B-cell Tumors","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Bio-gene Technology Co., Ltd","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia/Lymphoma","enrollment":12},{"nctId":"NCT05459870","phase":"PHASE1, PHASE2","title":"CAR-T Cells Targeting Autoimmune Diseases","status":"RECRUITING","sponsor":"Shenzhen Geno-Immune Medical Institute","startDate":"2022-07-31","conditions":"Autoimmune Diseases","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"BAFFR CAR-T","genericName":"BAFFR CAR-T","companyName":"Guangzhou Bio-gene Technology Co., Ltd","companyId":"guangzhou-bio-gene-technology-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAR-T cell therapy targeting BAFFR Used for Relapsed or refractory B-cell non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}